BHC Q1 2026 Earnings Call Summary

Summary of Bausch Health's Q1 2026 Earnings Call

1. Key Financial Results and Metrics

Revenue: $2.524 billion, up 12% year-over-year; organic growth of 7%.
Adjusted EBITDA: $837 million, a 27% increase year-over-year.
Adjusted Gross Margin: 70.9%, up 100 basis points from the previous year.
Adjusted Operating Cash Flow: $374 million.
Bausch Health (excluding Bausch & Lomb): Revenue of $1.280 billion, up 14% (9% organic); Adjusted EBITDA of $673 million, up 17%.
Cash Flow: Strong cash generation supported by solid operational performance, with net debt reduced by over $100 million.

2. Strategic Updates and Business Highlights

Core Business Performance: Continued growth driven by Salix (notably Xifaxan) and Solta, with Salix revenue up 18% and Solta revenue up 51% year-over-year.
R&D Initiatives: Progress on the larsucosterol Phase III program for alcohol-associated hepatitis, with a focus on a U.S.-only patient population and early randomization to improve outcomes.
Acquisition Impact: The integration of Shibo in China has significantly boosted Solta's performance, with a 193% revenue growth in that market.
AI Utilization: Enhanced commercial performance through AI-driven customer insights, leading to increased sales productivity and new patient starts for key products.

3. Forward Guidance and Outlook

2026 Guidance: Revenue expected between $5.250 billion and $5.400 billion; Adjusted EBITDA between $2.875 billion and $2.950 billion; Adjusted operating cash flow between $1.200 billion and $1.275 billion.
Market Dynamics: Anticipated impact of new tariffs on pharma products effective September 29, 2026, included in guidance.

4. Bad News, Challenges, or Points of Concern

Market Headwinds: Potential impacts from the exit from Medicaid and 340B programs may affect growth in the latter half of 2026.
Competitive Pressures: The impending generic competition for Xifaxan expected in January 2028 raises concerns about future revenue streams.
Tariff Exposure: Although current impacts are minimal, future tariffs could affect profitability, particularly in 2027.

5. Notable Q&A Insights

Xifaxan Inventory: Management does not anticipate significant destocking ahead of the IRA pricing step down in 2027.
Solta's Success in China: The integration of Shibo and strong demand for products are key factors driving growth; management is optimistic about sustainability.
Business Development Strategy: Focus on acquiring products that align with existing therapeutic areas and leveraging strong commercial capabilities for growth.
Contingency Planning: Preparedness for potential legal outcomes affecting exclusivity and cash flow generation, with options for refinancing and capital reallocation discussed.

Overall, Bausch Health reported a strong start to 2026, with solid financial performance and strategic initiatives in place, while also navigating potential challenges related to market dynamics and competitive pressures.

BHC — Bausch Health Companies Inc.